BMT Core at MCW brings advanced CAR T therapy for B-cell cancers
Official title: BMT Core- Medical College of Wisconsin
Funded at Medical College of Wisconsin · NIH-11398126 · Data updated 2026-11-12
A BMT Core Center at the Medical College of Wisconsin is testing a dual-target CAR T-cell therapy (CD19 and CD20) to help patients with difficult B-cell non-Hodgkin's lymphoma, including mantle cell lymphoma with high-risk features.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | July 27, 2017 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $234,000 |
| NIH project number | 5UG1HL138641-10 |
| Project ID | NIH-11398126 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma, including mantle cell lymphoma with high-risk features, who express CD19 and CD20.
✕Less likely to help
Patients with cancers lacking CD19/CD20 expression or those unable to tolerate CAR T-cell therapy may not benefit.
What this research studies
This grant supports MCW’s ongoing role as a core center for bone marrow transplant and cellular therapy, with a focus on sharing data and enabling trials. It describes development and testing of a first-in-human dual-target CAR T product (CAR20.19) for B-cell cancers and a phase I/II study in relapsed/refractory mantle cell lymphoma. The project builds on prior safety and preliminary efficacy data and aims to improve progression-free and overall survival for patients with high-risk features such as TP53 mutation and 17p deletions. The Center will contribute to trial accrual, data quality, and collaboration within the BMT CTN network.
Why it matters
Potential benefit: If successful, this approach could offer a more effective CAR T therapy for patients with high-risk B-cell malignancies.
How similar studies have gone: Early safety and dose data were promising and informed later phase studies; this continuation seeks to advance to broader Phase II testing.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Shah, Nirav — Medical College of Wisconsin
- Study coordinator: Shah, Nirav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.